fbpx
Digital - Business - Media

Mountain Valley MD To Include Testing Of South African Mutation In Upcoming COVID-19 BSL-4 Clearance Work

TORONTO, ON – February 22, 2021Mountain Valley MD Holdings Inc (CNSX:MVMD) (OTCMKTS:MVMDF) is pleased to announce that it will be testing the new B.1.351 South African COVID-19 variant in its upcoming Bio Safety Level 4 (“BSL-4”) lab study, which is analyzing viral clearance efficacy with the Company’s new solubilized Ivermectin technology.

According to the World Health Organization, the mutated B.1.351 COVID-19 variant is now the most dominant form of the COVID-19 virus in South Africa and is believed to be more infectious and thus easier to spread. As the COVID-19 virus continually mutates, researchers are assessing the impact of the current vaccines that are in distribution to understand if they may be rendered less effective or even noneffective*.

We felt it was critical to look at this new South African COVID-19 variant given the immediate complexities we are seeing with the pace of vaccine rollout and the high probability that current vaccines will not be as effective, if at all, against these emerging mutations. It is important to us across our broad human health objectives that our solubilized Ivermectin technology can be confidently applied as the broadest COVID-19 therapeutic and number one choice in the world when a vaccine falls short.

Dennis Hancock, President and CEO of Mountain Valley MD

Mountain Valley MD has previously communicated that it believes its solubilized Ivermectin would be suitable for a broad therapeutic across a wide range of viruses in the future, not just limited to COVID-19.

“It is not clear if the current vaccines will protect you from the new variants and early information is that vaccines are not as effective on the mutations. We are attempting in our work with the BSL-4 lab to target novel COVID-19 variants that would prove Ivermectin’s broad activity in interfering with the replication of the virus and thus broadly applies across multiple variants versus being specific to a variant the way a vaccine would be,” stated Mike Farber, Director of Life Sciences at MVMD.

As communicated in the Company’s news release on January 27, 2021, the BSL-4 trial will be the first of its kind ever conducted with human grade solubilized Ivermectin anywhere in the world and its design was led by the Company’s key scientific advisor, Dr. John Clements. Dr. Clements is Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine and has over 35 years of experience in vaccine, immunology and infectious diseases research and development, with a distinguished scientific career focused on developing and evaluating vaccines for a wide range of infectious diseases globally.

As previously communicated, MVMD’s solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

To view the original press release, click here.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More